Venous Thromboembolism Prevention in Outpatients With Glioma

Part of paid clinical trials in Burlington, Vermont.

Sponsor
University of Vermont Medical Center
Study ID
NCT05683808
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apixaban — DRUG
    Open label

Study Details

This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.

Key Dates

Start date
Jan 16, 2023
Status verified
Dec 2025
Primary completion
Dec 30, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Single arm study

Primary Outcome Measure

Safety of apixaban as determined by bleeding risk [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Vermont Medical CenterBurlingtonVermont05401-

Find similar trials in Burlington, VT

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of Vermont Medical Center· Burlington, VT

Related Studies